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ABSTRACT. The need to monitor, measure, and control sub-visible proteinaceous particulates in
biopharmaceutical formulations has been emphasized in recent publications and commentaries. Some of
these particulates can be highly transparent, fragile, and unstable. In addition, for much of the size range
of concern, no practical measurement method with adequate sensitivity and repeatability has been
available. A complication in measuring protein particulates in many formulations is the simultaneous
presence of other particle types such as silicone micro-droplets, air bubbles, and extrinsic contaminants.
The need has therefore been identiﬁed for new analytical methods which can accurately measure and
characterize sub-visible particulates in formulations. Micro-ﬂow imaging has been shown to provide high
sensitivity in detecting and imaging transparent protein particles and a unique capability to independently
analyze such populations even when other particle types are present.
KEY WORDS: light obscuration; micro-ﬂow imaging; particle sizing; protein aggregation; protein
formulation.
INTRODUCTION
Recent commentaries have stressed a need for character-
izing sub-visible particle populations in protein drug formu-
lations (1). Particles of primary concern are protein
aggregates in the size range from approximately 0.1 to
50 µm. For particles larger than 1 μm, often present in
relatively low concentrations, individual particle rather than
composite population measurement techniques are applicable.
A complication in measuring protein particulates in many
formulations is the simultaneous presence of other particle
types such as silicone oil micro-droplets, air bubbles, and
extrinsic contaminants. A measurement method which could
isolate different particle sub-populations would thus be
highly desirable. Light obscuration (LO) and membrane
microscopy are the standard methods for measuring
extrinsic particles >10 μm. However, these techniques
underestimate populations of smaller transparent particles
(2,3), are highly material dependent, and cannot distinguish
sub-populations. Therefore, these technologies are not
ideal for this application, and no other practical measure-
ment method having adequate sensitivity and accuracy has
been available. These challenges have led to an interest in
alternative technologies which are less dependent on
particle properties and can provide additional information
on particle parameters.
Micro-ﬂow imaging (MFI) has been shown to provide
high sensitivity in detecting and imaging transparent particles
and a unique capability to differentiate sub-populations of
particles having different morphologies using image ﬁltering
(4,5). This paper reviews work carried out by Brightwell and
its collaborators in evaluating, optimizing, and applying MFI
technology to measure sub-visible particles in protein
formulations.
MFI TECHNOLOGY
MFI is a ﬂow microscopy technology, where bright ﬁeld
images are captured in successive frames as a continuous
sample stream passes through a ﬂow cell centered in the ﬁeld-
of-view of a custom magniﬁcation system having a well-
characterized and extended depth-of-ﬁeld. The instrument
conﬁguration is shown in Fig. 1. A standard bench-top MFI
conﬁguration uses a simple ﬂuidics system, where sample
ﬂuid is drawn either directly from a pipette tip or larger
container through the ﬂow cell using a peristaltic pump. The
combination of system magniﬁcation and ﬂow-cell depth
determines the accuracy of concentration measurement.
Concentration and parameter measurements are absolute
but may be re-veriﬁed using particle standards. Typical
sample volumes range from <0.25 to tens of milliliters. Frame
images displayed during operation provide immediate visual
feedback on the nature of the particle population in the
sample. The system software extracts particle images by using
a sensitive threshold to identify pixel groups which deﬁne
each particle. Successive frames, each containing many
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ment sensitivity for detecting near-transparent particles is
achieved by automatically optimizing threshold values, using
low-noise electronics, implementing noise reduction algo-
rithms, and compensating for all possible non-uniformities in
spatial and pulse-to-pulse illumination. Ten-bit grayscale
resolution is used to improve threshold accuracy.
Images are analyzed to compile a database containing
count, size, concentration, as well as a range of shape and
image contrast parameters. This database is interrogated by
the computer’s application software to produce parameter
distributions using histograms and scatter plots. The software
supports image ﬁltering by calculating a trial ﬁlter based on
user selected representative particles and then interacting
with the user to optimize this ﬁlter to extract similar particles
from the total population. This feature allows particle sub-
populations to be isolated and independently analyzed.
Particle images are available for veriﬁcation, further inves-
tigation, and analysis. Once a successful assay has been
developed and validated, the resulting protocol, including
run parameters, software ﬁlters, and report formats, can be
saved for future use.
Direct imaging particle measurement technologies have
a number of advantages over indirect obscuration or scatter-
ing-based measurements. They do not rely on a correlation
between particle size and the magnitude of a scattered or
obscured optical signal as calibrated using polystyrene
reference beads. Provided the contrast in the particle image
is sufﬁcient for the pixels to be resolved by the system
threshold, the particle will be detected and measured. No
calibration by the user is required. The particle images
captured by the system also provide qualitative and quanti-
tative information about the target particle population.
Qualiﬁcation studies based on National Institute of Standards
and Technology-traceable polystyrene beads have shown that
thetechnologycanmeethighstandardsforsizing,concentration
accuracy, and repeatability (3). Representative performance
parameters for MFI instrument conﬁgurations optimized for
applications related to sub-visible particle analysis in protein
formulation development are shown in Table I.
Work to be described in the sections below includes
comparison of MFI with USP <788> methods, measurement
studies on a variety of typical protein formulations, morpho-
logical software ﬁlter development, assessment of consistency
and repeatability of the technology, and optimization of MFI
technology for this application.
PROTEIN PARTICLES AND FLOW MICROSCOPY
Comparison of MFI and USP <788> Methods
An early study compared the performance of the MFI
technology with USP <788> method (manual microscopy and
light obscuration) for an engineered parenteral formulation
containing proteinaceous particles (3). For particle sizes in
the <788> size range (≥10 µm), the measured concentrations
for this sample type differed by one or more orders of
magnitude and became larger as the particle size increased.
Similar results have been reported using different protein-
based formulations in other pharmaceutical laboratories (5,6).
The signiﬁcantly lower count by manual microscopy is most
likely due to a combination of factors such as break-up of
Fig. 1. Micro-ﬂow imaging instrument conﬁguration
Table I. Typical Micro-Flow Imaging Performance Parameters
Parameters DPA-4100 model DPA-4200 model
Size range (µm) 2 to 300 1 to 70
Concentration range w/o dilution (counts/mL; 2.5 µm objects) 175,000 900,000
Analysis rate (µL/min) 193 150
Sampling efﬁciency (%) 85
Sizing accuracy (%; 5 µm particles) ±5
Concentration accuracy (%; 5 µm particles) ±10
Measurement outcome Particle size, concentration (counts/mL), and shape/morphology
Intended use/suitable for Research, development, and quality control
456 Sharma, King, Oma and Merchantaggregates during sample preparation protocol and operator
interpretation. The origin of the differences in results
between ﬂow microscopy and light obscuration has not
been fully investigated. One of the contributing factors is
likely to be the minimal refractive index difference between
protein particles and the carrier ﬂuid, producing obscuration
signals which are smaller than those obtained from calibra-
tion beads of equivalent size. This weaker interaction of
protein particles with the illumination source is directly
observed by visual inspection of recorded images from MFI
which show clear differences in intensity (transparency)
between typical protein aggregates and the polystyrene
reference beads (Table II).
To investigate the effects of refractive index matching
between target particles and their carrier ﬂuids, suspensions
of low refractive index glass beads were prepared in aqueous
carrier ﬂuids whose refractive index was increased with the
addition of ethylene glycol. The effect of increasing refractive
index can be seen in Figs. 2a (LO), and 2b (MFI). These
ﬁgures show size and concentration measurements for a
population of 4.80 µm low refractive index glass beads
(refractive index 1.43 to 1.46 at 589 nm) suspended in water
(refractive index ∼1.33) and in a solution of 40% (v/v)
ethylene glycol in water (refractive index ∼1.37). Measure-
ments are in agreement between the two techniques when the
beads are suspended in water. However, signiﬁcant under-
sizing is seen for the light obscuration measurement in the
higher refractive index ethylene glycol mixture, while ﬂow
microscopy results are almost unaffected. The refractive
index of various protein aggregates have been reported in
the range of 1.33 to 1.40 (7,8) versus 1.59 for polystyrene bead
standards. While less susceptible to these effects than light
obscuration, results obtained by ﬂow microscopy can also be
affected by particle transparency. For highly transparent
particles found in some formulations, the contrast of some
or all of the pixels in the particle image may not be sufﬁcient
to trigger the system threshold. These particles will then be
under-sized, seen as fragmented images or missed entirely.
Post-analysis of saved images can be used to determine
whether particles are being under-sized or fragmented. With
proper choice of instrument conﬁguration, these effects can
be minimized for samples containing protein particles.
While refractive index matching of particle and carrier
ﬂuid may be an important component in the differences seen
between measurement techniques, other factors could also
contribute. These include:
& Differences in the optical absorption of proteins at
different wavelengths (in this case the LO light source
wavelength was 780 nm and the ﬂow microscope light
source was 470 nm)
& Impact of particle morphology on sizing
& Particle fragmentation at higher shear forces induced
by higher ﬂow rates in LO
& Undetected coincidence effects in LO
& Particle settling or fragmentation resulting from
inadequate or excessive magnetic stirring in LO
Application Studies on Protein Formulations
To evaluate the suitability of MFI for characterizing sub-
visible particles in protein formulations, the technique has
been applied to a variety of formulation and aggregate types
which might be encountered in the development and
manufacturing of bio-pharmaceuticals.
Stress-Induced Aggregates
Processes such as fermentation, puriﬁcation, formulation,
ﬁlling, shipment, and storage that can result in stress induced
aggregation are always encountered during manufacturing of
bio-pharmaceuticals (9–12). Stress-induced aggregate popula-
tions were produced by a freeze–thaw procedure in a protein
formulation containing monoclonal IgG1 antibody (1 mg/mL)
as the model protein in phosphate-buffered saline (PBS) buffer
(pH7.0±0.2). The count, size, and morphological characteristics
of the protein particulates were analyzed using MFI (4). The
protein particles or aggregates were observed to be highly
heterogeneousinshape,rangingfromsmalldenseﬁberstolarge
ribbon-like aggregates. Figure 3 contains representative images
of protein aggregates with a wide range of values for the
morphological parameters such as circularity, aspect ratio and
intensity.
Table II. Comparison between Protein Particles and Polystyrene Beads
Polystyrene beads 
 
Parameters         
Size (µm)  10 20  30  50 
463.47 316.62  249.22  182.54 
0.93 0.92  0.94  0.94 
Protein particles 
Parameters       
 
Size (µm)  10 20  30  50 
746.87 730.6  687.73  632.29 
0.64 0.48  0.39  0.26 
Intensity mean (0   1023)
Intensity mean (0   1023)
Circularity (0   1) 
Circularity (0   1) 
457 MFI Applied to Sub-visible Particulate AnalysisIn a further study of stress-induced aggregates (5),
protein particles were induced by shaking a model protein
formulation IMGN901 (13) provided by ImmunoGen
(Waltham, MA, USA) at a concentration of 1 mg/mL.
The number and size distribution of these aggregates were
measured by MFI and LO. Differences in the number of
particles measured by the two techniques were similar to
earlier results. MFI images also showed that the shape of
the protein particulates changed during agitation (images
not shown).
Evaluation of Filtrate Liquids
Filtering (normally 0.22 μm) is employed for parenteral
products to remove particles in the USP <788> size range. To
investigate the effect of ﬁltration on the number and size
distribution of protein particles, formulation samples containing
agitation stress-induced aggregates were measured pre- and
post-ﬁltration (0.22 μm membrane ﬁlter, Millipore, USA) by
MFI and LO techniques (5). Results again showed that MFI
measured more particles (by two orders of magnitude) than LO
Fig. 2. Measurement of low refractive index glass beads by (a) LO and (b) MFI. Signiﬁcant under-sizing is
seen for the light obscuration measurement in the higher refractive index ethylene glycol mixture (40%, v/v)
while ﬂow microscopy results were almost unaffected
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While it appears that ﬁltration can substantially reduce the
concentration of protein particles, particles may still be observed
downstream of an intact ﬁlter (14,15). It is unknown whether
these particles passed through the ﬁlter or were generated by the
process of ﬁltration. The data also suggest that ﬁltration’s
effectiveness is dependent on the initial number of sub-visible
particles present. This may have implications on strategies to
minimize or eliminate administration of protein particles.
High-Concentration Protein Formulations
In order to develop drugs requiring higher dosages, higher
concentrations (>100 mg/mL) are often employed in protein
formulations (16). Properties of such formulations can pose
additional challenges to particle measurement techniques. In
addition to accelerated aggregation rates at high protein
concentrations, high-concentration antibody formulations may
exhibit increased opalescence and viscosity (17). Studies have
been conducted using MFI on formulations having protein
concentrations ranging from 60 to 150 mg/mL with varying
opalescence, viscosity, and carrier ﬂuid refractive index.
Opalescence
The enhanced opalescence of concentrated monoclonal
antibody (mAb) solutions is expected to decrease the contrast
between the medium and the translucent proteinaceous
particles, potentially making their detection more challenging
for any optical measurement. A study was performed to
investigate the accuracy of MFI to size and count particles
(polystyrene and glass beads) and proteinaceous particles in a
concentrated antibody solution (∼60 mg/mL) with a neph-
elometric turbidity of 15 NTUs (18). Results showed that MFI
can detect proteinaceous particles, even in the context of
opalescent formulations. The sizing and concentration accu-
racy of MFI for polystyrene and glass particles, representing
different particle refractive index and transparency character-
istics, was unaffected by the opalescence of the medium. MFI
also demonstrated a high degree of linearity for quantifying
proteinaceous particles in opalescent solutions over a wide
range of particle concentrations (∼20 to 160,000 particles/
mL). These particles were signiﬁcantly underestimated by the
LO and manual microscopic technique, particularly those in
the 2–10-µm size range. The results obtained during this study
suggest that, to ensure comprehensive detection of partic-
ulates when analyzing opalescent solutions, it is important to
use ﬁltered protein solutions instead of buffer for illumination
optimization of MFI.
Viscosity
Higher protein concentration formulations often have
higher viscosities (17). To investigate the effect of increasing
viscosity,solutionsof10,20,30,40,and50cPwerepreparedusing
carboxymethyl cellulose in ﬁltered water. Viscosities were
measured using a Gilmont Viscometer (Thermo Fisher Scientiﬁc,
USA) at room temperature. These solutions were spiked with a
nominal concentration of 40,000 particles/mL of 10 µm polystyr-
ene beads, and the particle size and concentration was measured
using MFI. Results showed that the viscosity of the solutions did
not impactthe calibration of the pump and thevolumedispensed.
Size measurements were accurate to ±0.02 µm for all viscosities.
However, reductions in measured concentrations of 10% to 17%
wereobservedforhigherviscositysamples.Potentialcontributors
tothesereductionsincludesamplepreparation,particleadhesion,
and variations in the ﬂow characteristics of the system. These are
currently being investigated.
Carrier Refractive Index
A further observation in high-concentration protein
s a m p l e si st h ei n c r e a s e drefractive index of the ﬂuid
component relative to any particles which are present. As
previously discussed, this could result in a reduction in
contrast, causing a reduced efﬁciency in detecting highly
transparent particles. During one such study, a concentrated
monoclonal antibody formulation (150 mg/mL) with a
viscosity of 10 cP was used to investigate the accuracy and
precision of MFI. The protein formulation was spiked with a
known population of silicone oil droplets and serially diluted
with the formulating buffer to evaluate the linearity of
Fig. 3. Representative images of protein particles (size range from 25 to 354 µm) observed by MFI in
parenteral samples. The protein particles were observed to be highly heterogeneous in shape, ranging from
small dense ﬁbers to large ribbon-like aggregates
459 MFI Applied to Sub-visible Particulate Analysisconcentration measurement. Non-linear behavior was
observed in this particular formulation at higher dilutions.
This was initially attributed solely to the higher carrier ﬂuid
refractive indices associated with higher protein concentra-
tions. The refractive index of the 150-mg/mL mAb formula-
tion decreased progressively from 1.371 to 1.342 on dilution.
Subsequent work showed that the dilution process itself
rapidly produced additional particulates in this particular
formulation. The degree of additional particulate formation
also depended greatly on the sample preparation protocol.
Further work is underway on instrument conﬁgurations and
test protocols to understand these effects.
USING MORPHOLOGY FILTERS TO ISOLATE
PARTICLE SUB-POPULATIONS
A sub-population of particles which possesses distinct
particle morphology may be isolated using the image ﬁltering
capabilities of MFI. Diffraction and pixilation effects limit the
minimum particle size where additional useful morphological
parameters can be obtained. This limit is approximately 4 μm
for typically conﬁgured instruments as shown in Table I.
Morphology-based ﬁltering has been used to separate several
of the sub-population types which are often found along with
protein particles.
Silicone oil micro-droplets derived from detached lubri-
cants are often present in protein formulations (19). It is
desirable that sub-populations of protein aggregates and
silicone oil micro-droplets can be independently enumerated
when both are present in a sample. MFI has been successfully
used to accomplish this with an accuracy of ∼96% for
particles ≥5 µm employing a simple aspect ratio ﬁlter (3,4).
Air/gas bubbles can be also be present as a result of
handling processes, particularly in the case of reconstituted
lyophilized products. When measuring populations of solid
particles suspended in these ﬂuids, it is desirable that bubbles
can be identiﬁed and removed from the statistics. A drug
formulation sample which had exhibited high particle counts
≥10 µm when measured by LO was tested by MFI (3). A
circularity ﬁlter was ﬁrst applied to the MFI data to identify
single air bubbles. Remaining bubble clusters (coalescent air
bubbles) were identiﬁed using an intensity/aspect ratio ﬁlter.
An example of a ﬁltering application for multiple sub-
populations is shown in Fig. 4. The results show that the use of a
minimum intensity ﬁlter provides good separation between
protein particles, air bubbles, and silicone oil micro-droplets
suspended in PBS solutions. This separation can be further
improved by the use of a multi-parameter ﬁlter. When multiple
sub-populations and more complex objects are present, MFI
softwareprovidesasystematicmeansofdeveloping,testing,and
sequentially applying more multi-stage ﬁlters.
REPEATABILITY AND CONSISTENCY OF MFI
MEASUREMENT
The capabilities of MFI technology for measuring
protein formulations has already resulted in MFI being
widely employed for sub-visible particulate analysis during
formulation development. However, in order to be recog-
nized as a viable candidate for regulatory data collection and
quality assurance, MFI assays must be shown to provide
consistent and accurate measurements for the particle pop-
ulations found in the drug to which the assays will be applied.
Validation methods must ensure that measurements will be
consistent and repeatable for multiple instruments for the
manufacturing life of a formulation and must provide
accurate product monitoring with sensitive detection for out-
of-limit variations while avoiding unnecessary lot rejections
Fig. 4. Image ﬁltering capabilities of MFI. An intensity minimum ﬁlter was applied to a mixed particle
population to distinguish protein aggregates, silicone oil droplets, and air bubbles
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has been successfully applied to a range of drug types, the
speciﬁc properties of each new protein drug and its associated
particle population may inﬂuence the optimum protocol for
MFI testing, data analysis, and reporting. MFI methods
should be optimized and validated for each drug on which
they are to be applied. Properties which will inﬂuence MFI
testing protocol include the fragility and time stability of
particle populations, statistical accuracy requirements, settling
properties, turbidity, viscosity, and the presence of extrinsic
particles.
To illustrate the repeatability and consistency which
should reasonably be expected in routine testing for a
protein-based drug, intra-instrument and inter-instrument
variations were measured for a model protein drug formula-
tion (IgG1) at a concentration of 1 mg/mL. Sub-visible
protein aggregates were created in the IgG1 mAb solution
using a freeze–thaw method. The freeze–thaw method con-
sisted of repeatedly freezing the protein sample at −80°C for
5 min and immediately thawing in a warm water bath at 37°C
for 5 min. The freeze–thaw cycle was performed ﬁve times
above and beyond the original stock sample thaw. The
thawed sample was inverted several times to ensure proper
mixing and diluted 10-fold with ﬁltered placebo buffer (PBS,
pH7.0±0.2). The count and size of the protein particulates
were analyzed using MFI. Samples were introduced using
pipette tips. Prior to each sample run, particle-free ﬂuid was
ﬂushed through the system to provide a clean baseline. For
each sample and control, four separate runs of 1 mL each
were analyzed where the ﬁrst run was discarded and the
remaining three were averaged. Appropriate negative con-
trols were measured to ascertain the inﬂuence of the placebo
buffer. Three standard DPA 4200 instruments validated with
polystyrene beads and a sensitivity challenge standard were
employed during this study. Intra- and inter-instrument
variations in the total particle population were measured by
the three instruments as a function of the age of the protein
sample. Higher intra-instrument variability (RSDIntra 15%)
was observed in the initial particle count at 0 h (Fig. 5a),
indicating that particle population was initially unstable
following dilution with PBS. This is an example of the type
of instability which can invalidate dilution series measure-
ments on protein particles. The intra-instrument variability
decreased (RSDIntra 4%), after 1 h of incubation at room
temperature, demonstrating that the particle population
stabilized over time. It is hypothesized that, although the
protein particles were diluted with placebo buffer and there is
no change in solution conditions (except for a reduction in
protein concentration), the protein population appears to be
in an unstable state after initial dilution and requires time to
stabilize. This observation needs further investigation. Inter-
instrument variability was found to be small for all time
points measured compared to the intra-instrument variability.
Inter- and intra-instrument variations in the total particle
population also depended on particle size (Fig. 5b), as might
be expected from statistical factors, where higher variability
was seen in higher particle size ranges where fewer particles
were present. Results demonstrate that, for this typical
aggregate population, MFI measurements using appropriately
validated instruments and an optimized test protocol can
provide high repeatability and accuracy.
TECHNOLOGY OPTIMIZATION
As a result of protein particle studies, a number of areas
were identiﬁed where the MFI technology could be optimized
to better meet the requirements of this important but
challenging application. These include:
& Maximizing and controlling instrument sensitivity for
highly transparent particles
& Achieving high sampling efﬁciency for low sample
volume
& Minimizing shear stress on the sample
& Reducing the minimum volume of sample required
for a measurement
Maximizing and Controlling Instrument Sensitivity
Measurements on the same sample by different instru-
ments may vary depending on small variations in instrument
sensitivity (i.e., translucent particle detection). These effects
may be reduced by employing a ﬁxed threshold having the
minimum value consistent with optical noise. It was further
found that the range of optical adjustment where accurate
measurements of polystyrene beads can be obtained still
allows for signiﬁcant variations in the measurement of more
challenging protein particle populations. This was attributed
to the fact that polystyrene bead standards, unlike protein
particles, are easily detected and do not challenge the
sensitivity of the optical particle analyzer. A further sensitivity
challenge standard was required which would allow different
instruments to be assessed and adjusted to achieve consistent
results when very low contrast particles were present. Protein
particle populations themselves are not sufﬁciently stable or
repeatable for this purpose, especially when longer-term and
multi-site comparisons are required. To address this issue, a
stable, mineral-based suspension was identiﬁed which had
similar optical properties and measurement behavior as a
challenging protein aggregate population. Individual instru-
ments were then optically conﬁgured and veriﬁed for achieving
consistent particle distributions using this surrogate. This
approach was found to provide high sensitivity and minimize
inter-instrument differences. While general purpose MFIinstru-
ments can possess a number of magniﬁcation settings for use
with ﬂow cells of different depths, research with protein
aggregate formulations demonstrated that this ﬂexibility is not
consistent with the ﬁne adjustments required to obtain accept-
able repeatability between instruments. Single purpose, opti-
mized conﬁgurationscoveringthesizerangeofinterest(i.e.,1to
70 µm or 2 to 300 µm) could provide more consistent results.
Maximizing Sampling Efficiency
The sampling efﬁciency in MFI is the proportion of the
total ﬂuid volume passing through the ﬂow cell compared to
the ﬂuid which is captured in image frames. Because small
quantities of the sample ﬂuid lie outside the ﬁeld of view or
pass between successive frames, not all the sample which passes
through the ﬂow cell is analyzed, and thus, the sampling
efﬁciency is not 100%. When analyzing small volumes, inves-
tigating rare events, and adapting to existing sampling schemes,
it is desirable that sampling efﬁciency be well quantiﬁed and as
461 MFI Applied to Sub-visible Particulate Analysishigh as possible without particles appearing in successive
frames. By narrowing the ﬂow cell channel and arranging that
successive frames lie as close together as possible without
overlap, a sampling efﬁciency was achieved which exceeded
85%. The combination of high sampling efﬁciency and sensi-
tivity allows samples with only a few particles per milliliter to be
detected and accurately measured.
Minimizing Shear Forces
When delicate particles are subjected to shear forces
resulting from stirring or rapid sample ﬂow, particles may
fragment before they are measured. In protein-based drug
formulations, shear stresses can also result in the rapid
formation and growth of aggregate particles. The MFI sample
introduction system was modiﬁed to minimize shear forces by
using a gravity-assisted design to ensure large and dense
particles enter the viewing zone without the need for high ﬂow
rates. When stirring was required to maintain particles in
suspension, it was accomplished using gentle, adjustable, and
precise stirring system.
Minimizing Sample Volume Requirement
The volume of material available for particle analysis is
often very limited, especially in early stage formulation
development. By reducing the volume of ﬂuid in the sample
application lines and the ﬂow cell, ﬂushing requirements to
achieve clean baselines and minimum sample volumes are
reduced. A modiﬁed sample application port was developed
which directly accepts pipette tips or standard Luer con-
nections to larger sample containers. This facilitates obtaining
Fig. 5. Inter- and intra-MFI instrument repeatability (a); IgG1 particle sample reprodu-
cibility in various size ranges (b). Results demonstrate that, for this typical aggregate
population, MFI measurements using appropriately validated instruments and an
optimized test protocol can provide high repeatability and accuracy
462 Sharma, King, Oma and Merchantclean baselines and allows both smaller volume (<0.5 mL)
and larger volume samples to be conveniently introduced.
DISCUSSION
Currently, there are no regulatory limits for sub-visible
particles smaller than 10 µm. In a recently published
commentary, it was noted that there are critical gaps in the
detection and control of sub-visible proteinaceous particles,
especially in the size range 0.1–10 µm and that these particles
may have immunogenic potential (1). In this review, we have
described the capability of MFI to measure proteinaceous
particle populations. Results show that the MFI technique
provides high sensitivity in measuring such particles, the
capability to independently analyze sub-populations, and
yields additional insights provided by particle images.
Measurements made by MFI have been compared with
those obtained by LO and membrane microscopy. For the
range of sample types evaluated, these standard techniques
were found to detect a small proportion of the particles
present, and this may not be adequately representative of the
total sub-visible population. The lack of sensitivity in LO in
detecting transparent protein particles in carrier ﬂuids of
similar refractive index has been shown to be in part due to
the technique’s calibration method. Assessing the absolute
accuracy of any method in this application is compounded by
the absence of consensus protein particle standards.
Work on a variety of protein formulations has shown that
a number of sample-speciﬁc factors including opacity, viscos-
ity, and particle transparency should be considered in design-
ing and validating an MFI-based measurement protocol for a
particular drug. One notable observation in some formula-
tions is the potential for rapid formation of additional
particles following dilution. This effect can preclude the use
of dilution series with these formulations as an element of
method validation.
Areas of optimization for MFI technology to better meet
the requirements for protein particle measurement have been
described. In the course of investigating the validation of the
technology for quality assurance applications, intra- and inter-
instrument variability studies have been performed for
optimized instruments using a model aggregate population
and model measurement protocol. These have demonstrated
the potential for obtaining highly consistent results from the
technology.
CONCLUSION
Flow microscopy is an emerging technology which, when
suitably optimized, can provide a number of advantages over
existing techniques in the analysis of sub-visible particles in
protein formulations. These include:
& Improved sensitivity and accuracy
& Measurements which are less dependent on particle
composition
& Minimal sample stress
& Software-based identiﬁcation and ﬁltering of particle
sub-populations
The advantages of MFI are proving to be of value in a
range of tasks in formulation research and development (2–
6). Further experience and reﬁnement in the technology may
result in its use as an accepted method for performing
measurements on sub-visible particles in protein formula-
tions. Such measurements could assist in minimizing protein
aggregation and in maintaining the consistency in the size
distribution and morphology of residual particle populations
during formulation development, clinical trials, manufactur-
ing, and storage.
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